Saint Michael's Medical Center | ClinicalTrials HQ

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer	breast adenocarcinoma	Active, not recruiting	Phase 3	2026-10-01		NCT00433511
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)	Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder	Active, not recruiting	Phase 3	2026-10-01		NCT00310180
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1	HIV-1-infection	Recruiting	Phase 2	2026-09-04		NCT07645287
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen	HIV-1-infection	Active, not recruiting	Phase 2 / Phase 3	2026-08-10		NCT05502341
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction	acute myocardial infarction	Enrolling by invitation	Phase 3	2026-07-23		NCT04957719
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy	HIV-1-infection	Active, not recruiting	Phase 3	2026-06-15		NCT06333808
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1	HIV-1-Infection	Active, not recruiting	Phase 3	2026-05-29		NCT06630299
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1	HIV-1-infection	Active, not recruiting	Phase 3	2026-04-30		NCT06630286
Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed	HIV-1-Infection	Active, not recruiting	Phase 2 / Phase 3	2026-04-17		NCT06544733